BioCentury
ARTICLE | Company News

Amgen to pay rebates tied to Repatha outcomes

May 2, 2017 11:58 PM UTC

In a deal with regional insurer Harvard Pilgrim Health Care Inc. (Boston, Mass.), Amgen Inc. (NASDAQ:AMGN) agreed to pay rebates for the cost of cholesterol-lowering drug Repatha evolocumab to patients who have a heart attack or stroke while taking the drug. Amgen spokesperson Kristen Neese told BioCentury the rebate will be available to patients who have been treated with Repatha for at least six months.

Repatha, a PCSK9 inhibitor, is approved as adjunct therapy to lower LDL-C in adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH) or atherosclerotic cardiovascular disease (ASCVD)...